Glaukos Co. (NYSE:GKOS) Shares Purchased by Allspring Global Investments Holdings LLC

Allspring Global Investments Holdings LLC increased its stake in shares of Glaukos Co. (NYSE:GKOS) by 3,894.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 72,978 shares of the medical instruments supplier’s stock after purchasing an additional 71,151 shares during the period. Allspring Global Investments Holdings LLC owned 0.15% of Glaukos worth $5,801,000 as of its most recent SEC filing.

Other institutional investors have also recently modified their holdings of the company. Vanguard Group Inc. raised its holdings in Glaukos by 0.4% in the 3rd quarter. Vanguard Group Inc. now owns 5,380,720 shares of the medical instruments supplier’s stock valued at $286,470,000 after acquiring an additional 23,473 shares during the last quarter. Braidwell LP raised its holdings in Glaukos by 8.7% in the 1st quarter. Braidwell LP now owns 1,806,651 shares of the medical instruments supplier’s stock valued at $90,513,000 after acquiring an additional 144,800 shares during the last quarter. State Street Corp raised its holdings in Glaukos by 1.8% in the 2nd quarter. State Street Corp now owns 1,782,347 shares of the medical instruments supplier’s stock valued at $126,921,000 after acquiring an additional 31,471 shares during the last quarter. Fred Alger Management LLC raised its holdings in Glaukos by 9.2% in the 3rd quarter. Fred Alger Management LLC now owns 1,780,690 shares of the medical instruments supplier’s stock valued at $133,997,000 after acquiring an additional 150,102 shares during the last quarter. Finally, Invesco Ltd. raised its holdings in Glaukos by 45.5% in the 3rd quarter. Invesco Ltd. now owns 1,450,033 shares of the medical instruments supplier’s stock valued at $109,115,000 after acquiring an additional 453,756 shares during the last quarter. 99.04% of the stock is currently owned by institutional investors and hedge funds.

Glaukos Stock Performance

Shares of NYSE GKOS opened at $95.15 on Friday. The company has a quick ratio of 4.78, a current ratio of 5.34 and a debt-to-equity ratio of 0.77. The firm’s 50-day moving average price is $91.88 and its two-hundred day moving average price is $80.55. Glaukos Co. has a 52-week low of $45.38 and a 52-week high of $102.33. The stock has a market capitalization of $4.71 billion, a P/E ratio of -34.23 and a beta of 1.08.

Glaukos (NYSE:GKOS) last issued its earnings results on Wednesday, February 21st. The medical instruments supplier reported ($0.63) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.07). Glaukos had a negative return on equity of 22.67% and a negative net margin of 42.79%. The business had revenue of $82.40 million during the quarter, compared to the consensus estimate of $81.00 million. During the same period in the prior year, the business earned ($0.53) EPS. The business’s revenue was up 15.7% on a year-over-year basis. As a group, sell-side analysts forecast that Glaukos Co. will post -2.18 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts have weighed in on the company. Wells Fargo & Company boosted their price target on Glaukos from $83.00 to $103.00 and gave the company an “overweight” rating in a report on Thursday, February 22nd. Piper Sandler boosted their price target on Glaukos from $90.00 to $105.00 and gave the company an “overweight” rating in a report on Friday, December 22nd. Stifel Nicolaus reissued a “buy” rating and set a $110.00 price objective on shares of Glaukos in a research note on Wednesday, April 3rd. Needham & Company LLC boosted their price objective on shares of Glaukos from $105.00 to $108.00 and gave the company a “buy” rating in a research note on Thursday, February 22nd. Finally, Mizuho boosted their price objective on shares of Glaukos from $85.00 to $100.00 and gave the company a “neutral” rating in a research note on Thursday, April 11th. One research analyst has rated the stock with a sell rating, two have given a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat.com, Glaukos presently has a consensus rating of “Moderate Buy” and an average target price of $99.80.

Insider Activity

In other news, Director Mark J. Foley sold 4,560 shares of Glaukos stock in a transaction that occurred on Friday, February 23rd. The stock was sold at an average price of $92.87, for a total transaction of $423,487.20. Following the sale, the director now owns 33,220 shares of the company’s stock, valued at $3,085,141.40. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In related news, COO Joseph E. Gilliam sold 140,245 shares of the firm’s stock in a transaction that occurred on Friday, February 23rd. The shares were sold at an average price of $92.14, for a total transaction of $12,922,174.30. Following the transaction, the chief operating officer now owns 98,388 shares in the company, valued at $9,065,470.32. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Mark J. Foley sold 4,560 shares of the firm’s stock in a transaction that occurred on Friday, February 23rd. The shares were sold at an average price of $92.87, for a total transaction of $423,487.20. Following the transaction, the director now owns 33,220 shares in the company, valued at approximately $3,085,141.40. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 242,881 shares of company stock valued at $22,906,633. Insiders own 7.80% of the company’s stock.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.